As of 12:00 Noon Today, More Than 75% of Shares of Laboratorio Chile Tendered Into IVAX Offers.Business Editors/Health & Medical Writers MIAMI--(BUSINESS WIRE)--June 22, 2001 IVAX Corporation IVAX Corporation was a United States public corporation focused on manufacturing and distributing generic pharmaceutical products. Ivax was acquired by the Israeli company Teva Pharmaceutical Industries in January 2006. External links
See: American Stock Exchange :IVX) said that as of 12:00 noon today more than 75% of the shares, including shares represented by American Depositary Shares American Depositary Share (ADS) Foreign stock issued in the US and registered in the ADR system. of Laboratorio Chile S.A. had been tendered into its pending tender offers in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and in Chile. This exceeds the 67% required to be tendered prior to the shareholders meeting, scheduled to take place at 4:00 PM today. Both tender offers will expire at 12:00 midnight on Friday, June 29. IVAX Corporation, headquartered in Miami, Florida, is engaged in the research, development, manufacturing, and marketing of branded and brand equivalent pharmaceuticals and veterinary and diagnostic products in the U.S. and international markets. Except for the historical matters contained herein, statements in this press release are forward-looking. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect IVAX' business and prospects, including the risks that the shares may be withdrawn prior to the expiration date Expiration Date The day on which an options or futures contract is no longer valid and, therefore, ceases to exist. Notes: The expiration date for all listed stock options in the U.S. ; that the remaining conditions for the successful completion of the tender offer for Laboratorio Chile may not be satisfied; that upon completion of the tender offer IVAX IVAX Industrial Vax (Dec Computer) may not be able to integrate the operations of Laboratorio Chile without significant capital expenditures or other costs; that IVAX may not realize the anticipated benefits of the acquisition of Laboratorio Chile; that if the tender offer is completed that risks will arise from the operation of Laboratorio Chile; and other factors discussed in the Company's Annual Report on form 10K and other filings with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion